Skip to main content

Table 3 Efficacy of third-generation EGFR TKIs in EGFR T790M-positive NSCLC patients

From: Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

Drug

Trial

Patients (N)

Dose

ORR T790M

PFS (mo.)

Osimertinib

AURA phase I [92]

Total: 253 T790M(+): 138

20-240 mg QD

T790M(+): 61% T790M(−): 21%

T790M(+): 9.6 T790M(−): 2.8

AURA phase I T790M(+)

63

80 mg QD

71%

9.7

AURA phase II

210

80 mg QD

70%

9.9

AURA phase II extension [132]

411

80 mg QD

62%

12.3

AURA phase III [84]

416 -Osimertinib arm: 279

-Chemotherapy arm: 140

 

71%

31%

Odds ratio:5.39

(95% CI: 3.47–8.48)

10.1

4.4

HR: 0.30

(95% CI: 0.23–0.41)

Rociletinib

TIGER-X phase I/II [98]

Total: 69

T790M(+): 51

500, 625 or 750 mg bid

45%

T790M(+): 9.6

T790M(−): 2.8

Olmutinib

HM-EMSI-101 phase I/II T790M(+) [133]

76

800 mg QD

62%

6.9

ASP8273

NCT02113813 phase I/II [134]

Total: 63

T790M(+): 58

300 mg QD

29%

6.8

Nazartinib

NCT02108964 phase I/II [105]

152

75-350 mg QD

46.9%

9.7

Avitinib (AC0010)

NCT02330367 phase I/II [106]

136

50-350 mg QD

44%